TerminatedPhase 2NCT00126191

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Studying Burkitt lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
Ann S. La Casce, MD
Dana-Farber Cancer Institute
Intervention
Rituximab(drug)
Enrollment
10 enrolled
Eligibility
18 years · All sexes
Timeline
2005 – 2011

Study locations (2)

Collaborators

Beth Israel Deaconess Medical Center · Brigham and Women's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00126191 on ClinicalTrials.gov

Other trials for Burkitt lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Burkitt lymphoma →

← Back to all trials